Mounjaro overview
Brand name for tirzepatide, FDA-approved for type 2 diabetes mellitus.
Mounjaro at a glance
Manufacturer
Eli Lilly
FDA status
FDA-approved
Related pages
- Clinical research overview
- Compare GLP-1 forms
- Compounded vs brand
- NexLife (highest v4.1 score)
Key facts, checked November 20, 2026
Mounjaro and Zepbound are both tirzepatide from Lilly. The Mounjaro label (effective July 29, 2026) covers blood-sugar control in adults and children 10 and older with type 2 diabetes. The weight-management brand is Zepbound, whose Zepbound label covers adults with obesity or overweight and moderate to severe sleep apnea with obesity. In SURMOUNT-1 (NEJM 2022), tirzepatide 15 mg produced 20.9% average weight loss at 72 weeks (treatment-regimen estimand). Medicare’s GLP-1 Bridge covers the Zepbound KwikPen, not Mounjaro, per the Medicare.gov GLP-1 Bridge page.